ArticleMedicine2026
The association between lipid metabolism and coronary artery disease: A systematic Mendelian randomization study combined with transcriptome analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD), a chronic progressive inflammatory cardiovascular disorder and leading global cause of mortality, imposes a substantial worldwide economic burden. Identifying lipid metabolism-related genes linked to CAD is crucial for deepening our understanding of the disease's pathogenesis and discovering novel therapeutic targets. A total of 700 differentially expressed genes associated with CAD were determined by comparing CAD patients and healthy controls in the GSE250283 dataset. A positive relationship between lipid exposure and CAD was revealed by implementing a 2-sample Mendelian randomization analysis using genome-wide association studies data on lipid metabolism exposures and CAD outcomes. Further Mendelian randomization analysis, employing expression quantitative trait loci data from the identified differentially expressed genes as exposures and intersecting results with the Kyoto Encyclopedia of Genes and Genomes lipid metabolism pathway, identified 19 key genes exhibiting both lipid regulatory characteristics and reliable causal associations with CAD. Finally, 5 biomarker genes (SCP2, TNFAIP8, HMGCR, AGPAT3, and MAPKAPK2) were selected from the key genes by implementing 4 machine learning algorithms, and the developed nomogram incorporating these biomarkers demonstrated superior predictive accuracy for CAD risk stratification. The identification of these 5 genes as causal lipid metabolism biomarkers of CAD offers novel insights with high clinical potential, providing valuable targets for the management and treatment of CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.